This study explores Thrombospondin-4 as a cerebrospinal fluid biomarker for therapy response in pediatric SMA patients, highlighting its potential for treatment monitoring.
This study utilizes a multistage sequencing strategy to uncover novel candidate alleles for Emery-Dreifuss muscular dystrophy and supports gene misregulation as a key pathomechanism.